{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-058351","form_type":"8-K","ticker":"ELOX","cik":"0001035354","company_name":"Eloxx Pharmaceuticals, Inc.","filed_at":"2022-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.407787+00:00","generated_at":"2026-06-25T21:23:37.215645+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Eloxx Q1 net loss $11.6M; CF award up to $15.9M; cash into Q2 2023","bullets":["Net loss $11.6M ($0.13/sh) vs $8.7M ($0.22/sh) in Q1 2021; R&D $7.9M, G&A $3.1M.","CF Foundation award up to $15.9M for ELX-02; Phase 2 CF topline results expected end H1 2022.","Expanded ELX-02 development to Alport syndrome; Phase 2 proof-of-concept trial for nonsense mutations starts H2 2022.","Cash $39.8M sufficient into Q2 2023; ZKN-013 IND for RDEB planned H2 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-058351","json":"https://secwatch.observer/filing/0001104659-22-058351.json","markdown":"https://secwatch.observer/filing/0001104659-22-058351.md","text":"https://secwatch.observer/filing/0001104659-22-058351.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1035354/000110465922058351/0001104659-22-058351-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1035354/000110465922058351/tm2215074d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T21:23:37.215645+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}